Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.47 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 6/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | FEN1 | P39748 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7288734 | 0.80 | KMT2A (0.42) | LMNAFEN1MEN1KMT2APOLB | |
| SCHEMBL4069462 | 0.79 | TSHR (0.47) | LMNATSHRKDM4EALDH1A1HSD17B10 | |
| SCHEMBL6050600 | 0.79 | KDM4E (0.43) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL7111537 | 0.78 | BAZ2B (0.47) | BAZ2BBAZ2ALMNATSHRKDM4E | |
| SCHEMBL9837365 | 0.78 | BAZ2B (0.53) | BAZ2BBAZ2ALMNATSHRKDM4E | |
| Water SCHEMBL9837052 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1HSD17B10MEN1KMT2A | |
| SCHEMBL9835705 | 0.76 | BAZ2B (0.54) | BAZ2BBAZ2ALMNATSHRKDM4E | |
| SCHEMBL6317490 | 0.76 | BAZ2B (0.47) | BAZ2BBAZ2ALMNATSHRKDM4E | |
| SCHEMBL6481160 | 0.75 | BAZ2B (0.47) | BAZ2BBAZ2ALMNATSHRKDM4E | |
| SCHEMBL6479967 | 0.75 | BAZ2B (0.47) | BAZ2BBAZ2ALMNATSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995173-B2 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. (US) | 2005-01-13 | — | — | US | disclosed |
| EP-1355647-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. Alamo Ventures I, LLC (US) | 2003-10-29 | — | — | EP | disclosed |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | R.T. ALAMO VENTURES I, LLC | 2003-07-10 | — | — | US | disclosed |
| US-6562838-B2 | Providing subject suffering from a symptoms of cardiovascular disease and a purified enantiomer preparation of flosequinan; administering preparation to subject under conditions such that symptom is reduced | R. T. ALAMO VENTURES I, L.L.C. | 2003-05-13 | — | — | US | disclosed |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-10 | — | — | US | disclosed |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | R.T. ALAMO VENTURES I, L.L.C, | 2002-10-03 | — | — | US | disclosed |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | R.T. ALAMO VENTURES I, L.L.C. | 2002-10-03 | — | — | US | disclosed |
| US-6458804-B1 | UTILIZATION OF PHARMACEUTICAL COMPOSITIONS COMPRISING QUINOLINONES (AND DERIVATIVES THEREOF) IN PATIENTS WITH SYMPTOMS OF A CENTRAL NERVOUS SYSTEM DISORDER WHO ARE OTHERWISE FREE OF CARDIAC DISEASE AND/OR WHO HAVE NOT BEEN | R.T. ALAMO VENTURESI, LLC | 2002-10-01 | — | — | US | disclosed |
| US-6451813-B1 | Treatment of gastroparesis in certain patient groups | R. T. ALAMO VENTURES I, LLC | 2002-09-17 | — | — | US | disclosed |
| WO-2002058703-A2 | THE TREATMENT OF SEXUAL DYSFUNCTION AND CARDIOVASCULAR DISEASE WITH QUINOLINONE ENANTIOMERS | R.T. ALAMO VENTURES I, LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0269295-B1 | THERAPEUTIC AGENTS | The Boots Company PLC (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4877793-A | CARDIOVASCULAR DISORDERS | THE BOOTS COMPANY, PLC (GB) | 1989-10-31 | — | — | US | disclosed |
| EP-0269295-A1 | Therapeutic agents | The Boots Company PLC (GB) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009866-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | BAZ2B 4857/4885BAZ2A 4546/4885LMNA 1679/4885 |
| US-20030130311-A1 | Methods for the treatment of central nervous system disorders in certain patient groups | PMP22, NLN, SLC6A2 | BAZ2B 4377/4885BAZ2A 3994/4885LMNA 3541/4885 |
| US-20020143031-A1 | Treatment of cardiovascular disease with quinolinone enantiomers | TNNT2, TNNI3, NOS3 | BAZ2B 4857/4885BAZ2A 4546/4885LMNA 1679/4885 |
| US-20020147215-A1 | METHODS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS IN CERTAIN PATIENT GROUPS | PMP22, NLN, SLC6A2 | BAZ2B 4377/4885BAZ2A 3994/4885LMNA 3541/4885 |
| US-20020143030-A1 | TREATMENT OF GASTROPARESIS IN CERTAIN PATIENT GROUPS | FABP6, SLC10A2, FABP2 | BAZ2B 4861/4885BAZ2A 4847/4885LMNA 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.